| Primary information |
|---|
| sequence ID | Seq_4219 |
| Peptide sequence | KITHRIHWESA |
| CancerPDF_ID | CancerPDF_ID927, CancerPDF_ID9465, |
| PMID | 19795908,26379225 |
| Protein Name | Complement C3,Complement C3 |
| UniprotKB Entry Name | CO3_HUMAN,CO3_HUMAN |
| Fluid | Plasma,Plasma |
| M/Z | 689.36,1377.72 |
| Charge | 2,NA |
| Mass (in Da) | NA,NA |
| fdr | NA,NA |
| Profiling Technique | LC-MS,MALDI-TOF |
| Peptide Identification technique | MALDI-TOF/TOF,MALDI-TOF/TOF |
| Quantification Technique | LC-MRM (multiple reaction monitoring),NA |
| Labelled/Label Free | Labelled,Label Free |
| FDR | less than 7%,NA |
| CancerPDF_ID | CancerPDF_ID927, CancerPDF_ID9465, |
| p-Value | NA,NA |
| Software | FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT (v 2.3) |
| Length | 11,11 |
| Cancer Type | Ductal adenocarcinoma of the pancreas (DAP),Colorectal cancer |
| Database | NCBI refseq Protein Database,UniprotKB |
| Modification | NA,NA |
| Number of Patients | "42 normal, 28 patients","94 patients with CRC, 23 with liver metastasis from CRC (histologically defined) and 34 subjects, which underwent colonoscopy and resulted negative" |
| Regulation | NA,"Expression levels similar for liver metastasis and controls, but for adenoma and CRC groups was higher than controls." |
| Validation | NA,NA |
| Sensitivity | NA,NA |
| Specificity | NA,NA |
| Accuracy | NA,NA |
| Peptide Atlas | NA |
| IEDB | 533899
|